Berkeley Lights IPO Presentation Deck
Our collaboration with Ginkgo
IG
5 Signed September 2019
5 Upfront payment
5 Ginkgo will pay up to $150mm
for (1) our workflow
development efforts and (2) use
of our products and services
5 Development and regulatory
milestone payments for each
antibody therapeutic developed
through Ginkgo use of certain
of our workflows for services for
a 3rd party¹
To the extent Ginkgo also receives such payments
Combines Berkeley Lights platform
with automated genetic engineering
foundries
GINKGO
BIOWORKS™
THE ORGANISM COMPANY
Drives jointly developed workflows
to provide continued growth and
output in efficiency of Ginkgo's
foundries
"We're improving our ability to
engineer biology every year and new
technologies like Berkeley Lights' platform
are essential to maintaining that pace
of improvement. The Berkeley Lights
team has already had an incredible
impact on pharma - including cell line
development and antibody discovery -
and we believe this partnership will bring
about a step-change in the speed and
scale at which we engineer biology for
applications across a variety of
industries. We hope to move not just
Ginkgo initiatives forward, but the entire
biotech sector."
Barry Canton,
CTO and Co-founder,
Ginkgo Bioworks
31View entire presentation